Sponsor:
Genelux Corporation
Code:
NCT05281471
Conditions
Platinum-resistant Ovarian Cancer
Platinum-refractory Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
High-grade Serous Ovarian Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
olvimulogene nanivacirepvec
Platinum chemotherapy: carboplatin (preferred) or cisplatin
Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Bevacizumab (or biosimilar)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-14. This information was provided to ClinicalTrials.gov by Genelux Corporation on 2025-11-05.